Stockscreener 앱 받기
0.92
2.23%
0.0201
Tscan Therapeutics Inc 주식(TCRX)의 최신 뉴스
Number of shareholders of TScan Therapeutics, Inc. – NASDAQ:TCRX - TradingView
TScan Therapeutics Inc (TCRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TScan Therapeutics Inc (TCRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
TScan Therapeutics Inc (TCRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TScan Therapeutics Inc (TCRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
TScan Therapeutics Inc (TCRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TScan Therapeutics Inc (TCRX) Institutional Confidence - TradingKey
TScan Therapeutics Inc (TCRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
TScan Therapeutics Inc (TCRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
TScan Therapeutics Inc (TCRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TScan Therapeutics (TCRX) Declines Sharply as Biotech Sector Headwinds IntensifySector Sentiment - newsline.com
Cellares and TScan to assess automated manufacturing of TSC-101 therapy - Yahoo Finance
Cellares, TScan Partner to Automate Manufacture of TCR-T Candidate - Contract Pharma
Cellares, TScan to evaluate automated manufacturing for TSC-101 By Investing.com - Investing.com Australia
Cellares, TScan to evaluate automated manufacturing for TSC-101 - Investing.com
Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies - Business Wire
TCRX Q1 2026 Earnings: Wider-than-Expected Loss as Pipeline Advances Without RevenueFinancial Summary - newsline.com
TScan Therapeutics Cuts Net Loss to 28 Million Dollars - asatunews.co.id
TScan Therapeutics, Inc. (TCRX) Reports Q1 2026 Results With Improved Net Loss - Insider Monkey
TScan Therapeutics hangs around $1.08; eyes on next week - Bez Kabli
TScan Therapeutics Q1 2026 Earnings: Wider-Than-Expected Loss as Pre-Revenue Biotech Advances Clinical PipelineEPS Growth Report - The Legal Advocate
TScan Therapeutics (TCRX) Rallies 3.9% as Shares Test Key Resistance LevelsPercent Below MA - The Legal Advocate
TScan Therapeutics Q1 2026 Earnings: Narrowing Loss Despite EPS Miss, Stock Gains on Pipeline ProgressConsensus Forecast Report - The Legal Advocate
TScan Therapeutics Expands Authorized Shares After Stockholder Vote - The Globe and Mail
TScan Therapeutics Analyst Ratings and Price Targets | NASDAQ:TCRX - Benzinga
TScan Therapeutics (TCRX) director granted stock options for 67,000 shares - Stock Titan
Baker-linked TScan (TCRX) director granted 67,000 stock options - Stock Titan
TScan Therapeutics (NASDAQ: TCRX) wins vote to double authorized common stock - Stock Titan
TScan Therapeutics (TCRX) director awarded 67,000 stock options at $0.9946 - Stock Titan
Director at TScan Therapeutics (NASDAQ: TCRX) granted 67,000 options - Stock Titan
TScan Therapeutics (TCRX) director receives 67,000 stock option grant - Stock Titan
TScan Therapeutics (TCRX) director granted stock options on 67,000 shares - Stock Titan
TScan Therapeutics (TCRX) Stock Analysis: +3.27% Gain — What to Watch 2026-05-20Low Volatility Picks - Newser
TScan Therapeutics (TCRX) at $1.00 — Buy, Sell, or Hold? 2026-05-18Price Surge Stocks - The Legal Advocate
TScan Therapeutics, Inc.Common Stock (NQ: TCRX - FinancialContent
BVF group reports near‑10% stake in TScan Therapeutics (NASDAQ: TCRX) - Stock Titan
TradingKey - TradingKey
TCRX SEC FilingsTscan Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
LifeSci Capital Maintains TScan Therapeutics(TCRX.US) With Buy Rating, Maintains Target Price $6 - Moomoo
The fundamentals driving TScan Therapeutics (TCRX) everyone should understand (Under Pressure) 2026-05-08Institutional Buying - newser.com
Wedbush Maintains TScan Therapeutics(TCRX.US) With Buy Rating, Maintains Target Price $5 - Moomoo
TScan Therapeutics, Inc. (TCRX) reports Q1 loss, lags revenue estimates - MSN
Buy Rating Reiterated on TSC-101 Ahead of Key ALLOHA Readouts and Pipeline Expansion; $6 Price Target Maintained - TipRanks
TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - Black Hills Pioneer
TScan Therapeutics Announces Q1 2026 Financial Results, Phase 3 TSC-101 Trial Launch, and Pipeline Updates - Minichart
TScan Therapeutics, Inc. 2026 Q1 10-Q Report: Financials, Risk Factors, and Forward-Looking Statements - Minichart
TScan Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
TScan Therapeutics, Inc. 1Q 2026: Revenue $982K, EPS $(0.22) — 10-Q Summary - TradingView
TScan Therapeutics Reports $175.3 Million in Cash Reserves, Funding Operations Into Second Half of 2028 - geneonline.com
TScan Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
TScan Therapeutics (NASDAQ: TCRX) narrows Q1 2026 loss as R&D declines and cash runway extends - Stock Titan
TScan Therapeutics (NASDAQ: TCRX) narrows Q1 loss, plans Phase 3 - Stock Titan
H.C. Wainwright Maintains TScan Therapeutics(TCRX.US) With Buy Rating, Maintains Target Price $7 - Moomoo
TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Average Rating of "Hold" from Brokerages - MarketBeat
Is TScan Therapeutics (TCRX) stock worth taking a position in - newser.com
0.74%
1.44%
자본화:
|
볼륨(24시간):